Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study
- 578 Downloads
To clarify the clinicopathological features of breast cancer in young females, surveillance data of the Registration Committee of the Japanese Breast Cancer Society were analyzed.
The clinicopathological characteristics were compared between young (<35) patients and non-young (≥35) patients among 109,617 records registered between 2004 and 2009.
The numbers of young and non-young patients were 2,982 (2.7 %) and 106,295 (97.0 %), respectively. The young patients had more cases of a familial history of breast cancer, more subjective symptoms, fewer bilateral tumors, lower BMIs, larger tumors, more positive lymph nodes, fewer instances of an ER-positive status, more instances of an HER2-positive status, more triple-negative tumors and more advanced TNM stages. The young patients more frequently received neoadjuvant chemotherapy and breast-conserving therapy (BCT) compared with the non-young patients. Eighty percent of all patients received adjuvant therapy. The young patients were more frequently treated with chemotherapy, molecular targeted therapy and radiation therapy than the non-young patients.
In this study, young patients with breast cancer were diagnosed at more advanced stages and had more endocrine-unresponsive tumors than non-young patients. Further prognostic analyses should be conducted in this cohort.
KeywordsBreast cancer in young females Surveillance data
We wish to thank Mr. Naohito Fukui, the NPO Japan Clinical Research Support Unit staff and the Japanese Breast Cancer Society for their collaboration on this study and their ongoing development, maintenance and improvement of this registry. This work was supported by a research fund from the Japanese Breast Cancer Society.
Conflict of interest
The authors declare that they have no conflicts of interest.
- 4.Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, et al. Poor outcome of hormone receptor positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea-A report from the Korean Breast Cancer Society. J Clin Oncol. 2007;25:2360–8.PubMedCrossRefGoogle Scholar
- 7.Pronzato P, Mustacchi G, DeMatteis A, Di Costanzo F, Rulli E, Floriani I, et al. Biological characteristics and medical treatment of breast cancer in young women—a featured population: results from the nora study. Int J Breast Cancer. 2011, Article ID 534256, doi: 10.4061/2011/534256.
- 8.Pagani O, O’Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998;34:632–40.PubMedCrossRefGoogle Scholar
- 9.The Japanese breast cancer society. General roles for clinical and pathological recording of breast cancer.16th ed. Histological Classification of breast tumors. Tokyo: The Japanese breast cancer society; 2008. 18–59.Google Scholar
- 10.The World Health Organization. World Health Organization histological typing of breast tumors. Am J Clin Pathol. 1982;78:806–16.Google Scholar
- 14.Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER cancer statistics review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.
- 24.Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remissionrate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factorreceptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.PubMedCrossRefGoogle Scholar
- 25.Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–44.PubMedCrossRefGoogle Scholar